Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study
Observational Study
[키워드] 95% CI
acute respiratory syndrome
adjusted
age
AstraZeneca
AZD1222
BNT162b2
calculated
conducted
control group
coronavirus
coronavirus disease
Coronavirus disease 2019-related death
Coronavirus-2
Coronavirusdisease 2019 infection
COVID-19
COVID-19-related death
database
demonstrated
disease
dose
Effectiveness
Estimated
FIVE
Gam-COVID-Vac
incidence rate
individual
Infection
Moderna
Mortality
mRNA-1273
original
Original submission
pandemic
Pfizer-BioNTech
Public
Real-world study
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 vaccine
second dose
Severe acute respiratory syndrome coronavirus-2 infection.
Sex
Sinopharm
Surveillance
vaccinated individuals
vaccination
Vaccine
Vaccines
[DOI] 10.1016/j.cmi.2021.11.011 PMC 바로가기 [Article Type] Observational Study
[DOI] 10.1016/j.cmi.2021.11.011 PMC 바로가기 [Article Type] Observational Study